Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CytoDyn Inc.CYDY · Entity 5856 | President | February 13, 2023 | February 15, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CytoDyn Inc.
Report date February 13, 2023 · Filed February 15, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,081,334 |
Reported balance
After 2023-02-13 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-02-13 · Grant · Acquired 434,782 · Balance 1,081,334 F1: The reported securities are included within Units purchased by the reporting person in a private placement directly with the Company. The terms are identical to a concurrent offering being conducted through a placement agent (the "Offering"). Each "Unit" consists of one share of common stock and one warrant to purchase one share of common stock. F2: The number of Units and the corresponding numbers of shares and warrants have been calculated based on a purchase price of $0.23 per Unit, which was equal to 90% of the intraday volume weighted average price of the common stock on January 12, 2023, the date of the first closing in the Offering. The number of Units and corresponding numbers of shares and warrants purchased in the Offering will increase if 90% of the intraday volume weighted average price of a share of common stock on the final closing date in the Offering is lower than $0.23. The revised numbers will be calculated by dividing $100,000 by such lower price. |
| Warrants (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.50 | Direct | 434,782 |
Reported balance
After 2023-02-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-02-13 · Grant · Acquired 434,782 · Balance 434,782 F1: The reported securities are included within Units purchased by the reporting person in a private placement directly with the Company. The terms are identical to a concurrent offering being conducted through a placement agent (the "Offering"). Each "Unit" consists of one share of common stock and one warrant to purchase one share of common stock. F2: The number of Units and the corresponding numbers of shares and warrants have been calculated based on a purchase price of $0.23 per Unit, which was equal to 90% of the intraday volume weighted average price of the common stock on January 12, 2023, the date of the first closing in the Offering. The number of Units and corresponding numbers of shares and warrants purchased in the Offering will increase if 90% of the intraday volume weighted average price of a share of common stock on the final closing date in the Offering is lower than $0.23. The revised numbers will be calculated by dividing $100,000 by such lower price. F3: The warrants will become exercisable in full on the final closing date of the Offering. The warrants will expire five years after the exercise date. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities are included within Units purchased by the reporting person in a private placement directly with the Company. The terms are identical to a concurrent offering being conducted through a placement agent (the "Offering"). Each "Unit" consists of one share of common stock and one warrant to purchase one share of common stock.
F2: The number of Units and the corresponding numbers of shares and warrants have been calculated based on a purchase price of $0.23 per Unit, which was equal to 90% of the intraday volume weighted average price of the common stock on January 12, 2023, the date of the first closing in the Offering. The number of Units and corresponding numbers of shares and warrants purchased in the Offering will increase if 90% of the intraday volume weighted average price of a share of common stock on the final closing date in the Offering is lower than $0.23. The revised numbers will be calculated by dividing $100,000 by such lower price.
F3: The warrants will become exercisable in full on the final closing date of the Offering. The warrants will expire five years after the exercise date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 13, 2023 Filed Feb 15, 2023 01:09 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantWarrants (right to buy) · Derivative | 434,782 | Not disclosed Strike: $0.50 | Not disclosed |
DisclosureSEC source: 0001104659-23-022094 · tm236870-1_4seq1.xml · derivative · entry 2 Arman Arvin Cyrus · CIK 0001939191 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 434,782 Underlying: Common Stock · 434,782 shares Expires not disclosed F1 · shares: The reported securities are included within Units purchased by the reporting person in a private placement directly with the Company. The terms are identical to a concurrent offering being conducted through a placement agent (the "Offering"). Each "Unit" consists of one share of common stock and one warrant to purchase one share of common stock. F2 · shares: The number of Units and the corresponding numbers of shares and warrants have been calculated based on a purchase price of $0.23 per Unit, which was equal to 90% of the intraday volume weighted average price of the common stock on January 12, 2023, the date of the first closing in the Offering. The number of Units and corresponding numbers of shares and warrants purchased in the Offering will increase if 90% of the intraday volume weighted average price of a share of common stock on the final closing date in the Offering is lower than $0.23. The revised numbers will be calculated by dividing $100,000 by such lower price. F2 · price: The number of Units and the corresponding numbers of shares and warrants have been calculated based on a purchase price of $0.23 per Unit, which was equal to 90% of the intraday volume weighted average price of the common stock on January 12, 2023, the date of the first closing in the Offering. The number of Units and corresponding numbers of shares and warrants purchased in the Offering will increase if 90% of the intraday volume weighted average price of a share of common stock on the final closing date in the Offering is lower than $0.23. The revised numbers will be calculated by dividing $100,000 by such lower price. F3 · derivative.exercise_date: The warrants will become exercisable in full on the final closing date of the Offering. The warrants will expire five years after the exercise date. F3 · derivative.expiration_date: The warrants will become exercisable in full on the final closing date of the Offering. The warrants will expire five years after the exercise date. F1 · derivative.underlying_shares: The reported securities are included within Units purchased by the reporting person in a private placement directly with the Company. The terms are identical to a concurrent offering being conducted through a placement agent (the "Offering"). Each "Unit" consists of one share of common stock and one warrant to purchase one share of common stock. F2 · derivative.underlying_shares: The number of Units and the corresponding numbers of shares and warrants have been calculated based on a purchase price of $0.23 per Unit, which was equal to 90% of the intraday volume weighted average price of the common stock on January 12, 2023, the date of the first closing in the Offering. The number of Units and corresponding numbers of shares and warrants purchased in the Offering will increase if 90% of the intraday volume weighted average price of a share of common stock on the final closing date in the Offering is lower than $0.23. The revised numbers will be calculated by dividing $100,000 by such lower price. F2 · balance_after: The number of Units and the corresponding numbers of shares and warrants have been calculated based on a purchase price of $0.23 per Unit, which was equal to 90% of the intraday volume weighted average price of the common stock on January 12, 2023, the date of the first closing in the Offering. The number of Units and corresponding numbers of shares and warrants purchased in the Offering will increase if 90% of the intraday volume weighted average price of a share of common stock on the final closing date in the Offering is lower than $0.23. The revised numbers will be calculated by dividing $100,000 by such lower price. Read SEC document |
| February 13, 2023 Filed Feb 15, 2023 01:09 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon Stock | 434,782 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-022094 · tm236870-1_4seq1.xml · nonDerivative · entry 1 Arman Arvin Cyrus · CIK 0001939191 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,081,334 F1 · shares: The reported securities are included within Units purchased by the reporting person in a private placement directly with the Company. The terms are identical to a concurrent offering being conducted through a placement agent (the "Offering"). Each "Unit" consists of one share of common stock and one warrant to purchase one share of common stock. F2 · shares: The number of Units and the corresponding numbers of shares and warrants have been calculated based on a purchase price of $0.23 per Unit, which was equal to 90% of the intraday volume weighted average price of the common stock on January 12, 2023, the date of the first closing in the Offering. The number of Units and corresponding numbers of shares and warrants purchased in the Offering will increase if 90% of the intraday volume weighted average price of a share of common stock on the final closing date in the Offering is lower than $0.23. The revised numbers will be calculated by dividing $100,000 by such lower price. F2 · price: The number of Units and the corresponding numbers of shares and warrants have been calculated based on a purchase price of $0.23 per Unit, which was equal to 90% of the intraday volume weighted average price of the common stock on January 12, 2023, the date of the first closing in the Offering. The number of Units and corresponding numbers of shares and warrants purchased in the Offering will increase if 90% of the intraday volume weighted average price of a share of common stock on the final closing date in the Offering is lower than $0.23. The revised numbers will be calculated by dividing $100,000 by such lower price. F2 · balance_after: The number of Units and the corresponding numbers of shares and warrants have been calculated based on a purchase price of $0.23 per Unit, which was equal to 90% of the intraday volume weighted average price of the common stock on January 12, 2023, the date of the first closing in the Offering. The number of Units and corresponding numbers of shares and warrants purchased in the Offering will increase if 90% of the intraday volume weighted average price of a share of common stock on the final closing date in the Offering is lower than $0.23. The revised numbers will be calculated by dividing $100,000 by such lower price. Read SEC document |
| September 20, 2022 Filed Sep 23, 2022 00:20 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantNon-qualified stock option (right to buy) · Derivative | 1,575,557 | $0.00 Strike: $0.58 | $0.00 |
DisclosureSEC source: 0001104659-22-102416 · tm2226067-4_4seq1.xml · derivative · entry 2 Arman Arvin Cyrus · CIK 0001939191 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,575,557 Underlying: Common Stock · 1,575,557 shares Expires 2032-09-20 F2 · derivative.exercise_date: 25% of the award will vest on July 9, 2023; thereafter, the balance will vest in 36 equal monthly installments, subject to Continuous Service (as the term is defined in the Plan) through the applicable vesting date. Read SEC document |
| September 20, 2022 Filed Sep 23, 2022 00:20 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon Stock | 646,552 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-102416 · tm2226067-4_4seq1.xml · nonDerivative · entry 1 Arman Arvin Cyrus · CIK 0001939191 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 646,552 F1 · security: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2012 Equity Incentive Plan, as amended (the "Plan"). The RSUs will vest in four (4) equal annual installments beginning July 9, 2023, subject to Continuous Service (as the term is defined in the Plan) through the applicable vesting date. F1 · shares: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2012 Equity Incentive Plan, as amended (the "Plan"). The RSUs will vest in four (4) equal annual installments beginning July 9, 2023, subject to Continuous Service (as the term is defined in the Plan) through the applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.